Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis

• Shuo Yang,

  Roles Writing – original draft, Writing – review & editing

  Affiliation School of Pharmacy, Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China

  https://orcid.org/0009-0000-6967-0908

  ⨯
• Yibing Hou,

  Roles Writing – original draft, Writing – review & editing

  Affiliation Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China

  ⨯
• Xiaohui Wang,

  Roles Writing – review & editing

  Affiliation Development Planning Division, Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China

  ⨯
• Shuo Kang ,

  Roles Writing – review & editing

  * E-mail: panzhenhua@hebmu.edu.cn (ZP); shuok628@hebmu.edu.cn (SK)

  Affiliation Development Planning Division, The Second Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China

  ⨯
• Zhenhua Pan

  Roles Writing – review & editing

  * E-mail: panzhenhua@hebmu.edu.cn (ZP); shuok628@hebmu.edu.cn (SK)

  Affiliation Development Planning Division, Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China

  https://orcid.org/0009-0000-3276-728X

  ⨯